INS19 CAR-T Cells therapy (Beijing Yimiao Medical Technology)

INS19 嵌合抗原受体T细胞（北京艺妙医疗科技）

Report date: 2026/01/13 17:30:24

Base Information

Drug NameINS19 CAR-T Cells therapy (Beijing Yimiao Medical Technology)
Drug Alias NameINS19 CAR-T细胞
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Yimiao Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Jinsai Biotechnology Co LtdImunopharm Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A